The biological toll of long-duration spaceflight has long been a concern for space agencies worldwide, but new research from Johns Hopkins Medicine provides some of the most detailed evidence to date regarding the impact of microgravity on human cardiac health. Scientists who sent 48 samples of human bioengineered heart tissue to the International Space Station (ISS) for a 30-day stay have reported that low-gravity conditions significantly weakened the tissues and disrupted their natural rhythmic contractions. When compared to control samples maintained on Earth, the space-bound tissues exhibited a dramatic decline in functional strength and showed signs of cellular distress typically associated with aging and heart disease.
The study, published in the Proceedings of the National Academy of Sciences during the week of Sept. 23, offers a sobering look at how the lack of gravity affects the human cardiovascular system at a cellular level. Lead researcher Deok-Ho Kim, Ph.D., a professor of biomedical engineering and medicine at the Johns Hopkins University School of Medicine, noted that the heart tissues "really don’t fare well in space." Over the course of the month-long mission, the tissues aboard the ISS beat with only about half the strength of their terrestrial counterparts. This research provides a critical foundation for understanding the risks faced by astronauts on future missions to the Moon and Mars, while also offering a unique model for studying heart muscle aging and potential therapies for patients on Earth.
Engineering the Cardiac Payload: From Stem Cells to Tissue Chips
The journey of these heart tissues began long before they reached the launchpad at Cape Canaveral. To create a viable model for space research, the team, led by scientist Jonathan Tsui, Ph.D., utilized human induced pluripotent stem cells (iPSCs). These are adult cells that have been genetically reprogrammed to an embryonic-like state, allowing them to be coaxed into becoming any cell type in the body. In this case, Tsui transformed the iPSCs into cardiomyocytes—the specialized muscle cells responsible for the heart’s ability to contract.
The challenge was not just creating the cells, but housing them in a way that would allow for real-time monitoring in the harsh environment of space. The team developed a sophisticated "tissue-on-a-chip" system. This bioengineered, miniaturized platform strings the heart tissues between two tiny posts within a chamber roughly half the size of a mobile phone. This 3D housing was meticulously designed to mimic the physical environment of an adult human heart, providing the necessary mechanical cues for the cells to function as they would in a living body.
The tissue chips were equipped with biosensors capable of measuring "twitch forces"—the strength of the muscle contractions—and tracking the timing of each beat. This microfabricated environment allowed the researchers to collect high-resolution data on the tissues’ performance without the need for large, cumbersome laboratory equipment.
Chronology of the SpaceX CRS-20 Mission
The project reached its operational phase in early 2020. The logistical hurdles were immense; because the heart tissues were living biological samples, they required constant care and a precise environment. Dr. Tsui hand-carried the tissue chambers on a commercial flight to Florida, where he spent a month at the Kennedy Space Center performing final preparations and ensuring the tissues remained healthy leading up to the launch.
In March 2020, the heart tissues were loaded onto the SpaceX CRS-20 mission, a commercial resupply flight bound for the ISS. Once the payload reached the orbiting laboratory, the experiment transitioned into its monitoring phase. For 30 days, the scientists back on Earth received real-time data bursts. Every 30 minutes, the system transmitted 10 seconds of data regarding the cells’ contraction strength and rhythm.
Onboard the ISS, the experiment was facilitated by Astronaut Jessica Meir, Ph.D., who managed the biological maintenance of the samples. Once a week, Meir replaced the liquid nutrients surrounding the tissues to keep them alive. At specific intervals, she preserved certain samples for later analysis, including gene readout and imaging, which could only be performed after the tissues returned to Earth. Meanwhile, a control set of identical cardiac tissues was maintained at Johns Hopkins under Earth’s gravity, housed in the same type of chambers to ensure that any observed differences were due to the space environment rather than the hardware itself.
Quantitative Analysis: Weakness and Arrhythmia in Orbit
The data returned from the ISS revealed a steady decline in cardiac function. The most striking finding was the loss of "twitch force." Within the first few weeks of exposure to microgravity, the tissues began to weaken. By the end of the 30-day period, the contractile strength of the space-bound heart muscle was approximately 50% less than that of the Earth-bound samples.
Beyond the loss of strength, the researchers observed significant disruptions in the tissues’ rhythm. In a healthy environment, cardiac tissue beats with a regular, predictable interval—usually about one second between beats. However, the samples on the ISS developed severe arrhythmias. The intervals between beats in the space-bound tissues grew to be nearly five times longer than those on Earth. These irregular patterns are a hallmark of cardiac dysfunction and, in a human patient, would be a precursor to heart failure.
Interestingly, the study noted a degree of resilience upon return. When the tissue chambers were brought back to Earth and re-exposed to normal gravity, the time between beats returned nearly to normal levels. However, the underlying cellular damage and the loss of contractile strength remained significant areas of concern.
Molecular and Structural Degradation
To understand why the tissues were failing, the research team performed deep-dive analyses into the cellular architecture and genetic expression of the samples. Devin Mair, Ph.D., a postdoctoral fellow at Johns Hopkins, led the analysis of the tissues’ ability to contract and their structural integrity.
The team focused on the sarcomeres—the protein bundles within muscle cells that act as the fundamental units of contraction. In the space-bound samples, these sarcomeres had become shorter and more disordered. This structural breakdown is a classic signature of human heart disease and explains the loss of twitch force observed during the mission.
The cellular "powerhouses," the mitochondria, also showed signs of significant stress. In a healthy heart cell, mitochondria have characteristic folds that maximize their efficiency in producing energy. In the space-bound cells, the mitochondria grew larger and rounder, losing those vital folds. This suggests that the cells were struggling to meet their energy demands, likely contributing to the overall weakening of the tissue.
Furthermore, a team including Eun Hyun Ahn, Ph.D., and Zhipeng Dong studied the gene readout of the tissues. They found a marked increase in the expression of genes associated with inflammation and oxidative damage. "Many of these markers of oxidative damage and inflammation are consistently demonstrated in post-flight checks of astronauts," Mair noted, bridging the gap between this cellular study and clinical observations of humans who have returned from space.
Broader Implications for Long-Duration Space Travel
This study adds a critical layer of cellular evidence to what NASA and other space agencies have observed in astronauts for decades. It has long been known that astronauts returning from the ISS often suffer from reduced heart muscle function and irregular heartbeats. While some of these effects dissipate over time, the long-term consequences of multi-year missions—such as a journey to Mars—remain unknown.
The Johns Hopkins research suggests that the heart does not simply "rest" in low gravity; it undergoes active degradation. The findings imply that without significant intervention, the cardiovascular systems of astronauts could undergo accelerated aging during long missions. This could lead to permanent damage that might not fully reverse upon return to Earth’s gravity.
The study also highlights the importance of the "tissue-on-a-chip" technology as a platform for drug discovery. Because the bioengineered tissues so closely mimic human heart disease in space, they provide an ideal testing ground for "countermeasures"—drugs or therapies designed to protect the heart from microgravity.
Future Research and Terrestrial Applications
The work of Dr. Kim’s lab is far from finished. In 2023, the team sent a second batch of 3D engineered heart tissues to the ISS. This follow-up study is specifically designed to screen for protective drugs that might mitigate the effects of low gravity. If successful, these drugs would not only be vital for astronauts but could also be repurposed to help elderly patients on Earth who suffer from age-related heart muscle weakening and sarcopenia.
Additionally, the researchers are now looking beyond gravity. The ISS orbits within the Earth’s magnetic field, which provides protection from the bulk of space radiation. However, missions to the Moon and Mars will expose astronauts to much higher levels of cosmic radiation. The Johns Hopkins team is currently using the NASA Space Radiation Laboratory to study how radiation combined with microgravity affects heart tissue.
As humanity stands on the precipice of becoming a multi-planetary species, understanding the cellular response to the space environment is no longer a matter of academic curiosity—it is a matter of survival. The insights gained from 48 tiny samples of heart tissue orbiting 250 miles above the Earth may eventually be what allows humans to safely travel millions of miles into the solar system. For now, the research serves as a stark reminder of the fragile nature of human biology and the incredible engineering required to sustain it beyond the confines of our home planet.
Leave a Reply